Kalvista
257 employees · 3 known investors
Find your way into Kalvista
KalVista Pharmaceuticals is a global biopharmaceutical company that develops oral therapies for rare diseases, starting with hereditary angioedema (HAE). Its pipeline includes preclinical oral Factor XIIa inhibitors targeting HAE prophylaxis as well as thrombosis and inflammation.
Investors · 3
In the news
Frequently asked questions
- What does Kalvista do?
- KalVista Pharmaceuticals is a global biopharmaceutical company that develops oral therapies for rare diseases, starting with hereditary angioedema (HAE). Its pipeline includes preclinical oral Factor XIIa inhibitors targeting HAE prophylaxis as well as thrombosis and inflammation.
- Who are Kalvista's investors?
- Kalvista's investors include Frazier Life Sciences, Longwood Fund, RA Capital.